XML 65 R12.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Note 6 - Acquired Intangible Assets, Net | 12 Months Ended
--- | ---
Dec. 31, 2019
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | 6. Acquired Intangible Assets, Net Intangible assets consist of the following:
|  |  |  | December 31, 2019 |  | December 31, 2018 |  |
|  | Gross Value |  | Accumulated Currency Translation Adjustment |  | Impairment |  | Accumulated Amortization |  | Net Book Value |  | Accumulated Currency Translation Adjustment |  | Accumulated Amortization |  | Net Book Value |  | Useful Life
Developed technology |  | $ | 17,100 |  |  | $ | (2,934 | ) |  | $ | (389 | ) |  | $ | (9,657 | ) |  | $ | 4,120 |  |  | $ | (2,824 | ) |  | $ | (8,672 | ) |  | $ | 5,604 |  |  | 15
In-process research & development |  |  | 4,406 |  |  |  | (1,234 | ) |  |  | – |  |  |  | – |  |  |  | 3,172 |  |  |  | (1,168 | ) |  |  | – |  |  |  | 3,238 |  |  | Indefinite
Distributor relationships |  |  | 4,700 |  |  |  | (415 | ) |  |  | – |  |  |  | (4,285 | ) |  |  | – |  |  |  | (415 | ) |  |  | (4,285 | ) |  |  | – |  |  | 5
Patents |  |  | 1,000 |  |  |  | (176 | ) |  |  | – |  |  |  | (531 | ) |  |  | 293 |  |  |  | (169 | ) |  |  | (482 | ) |  |  | 349 |  |  | 16
Elevess trade name |  |  | 1,000 |  |  |  | – |  |  |  | – |  |  |  | (1,000 | ) |  |  | – |  |  |  | – |  |  |  | (1,000 | ) |  |  | – |  |  | 9
Total |  | $ | 28,206 |  |  | $ | (4,759 | ) |  | $ | (389 | ) |  | $ | (15,473 | ) |  | $ | 7,585 |  |  | $ | (4,576 | ) |  | $ | (14,439 | ) |  | $ | 9,191 |  |  |
The Company performed an annual assessment of IPR&D intangible assets as of November 30, 2019. Based upon that assessment, for the fiscal year 2019 there were no events or changes in circumstances that would result in a change in the carrying value of IPR&D. Total amortization expense was $1.0 million for each of the years ended December 31, 2019, 2018, and 2017. Amortization expense on intangible assets is expected to be approximately $0.9 million in 2020, $0.9 million annually through 2023, and approximately $1.0 million in aggregate thereafter. The Company recorded a $0.4 million of impairments during 2019 including a $0.3 million impairment charge for the HYALOSPINE developed technology asset as the Company made the decision not to renew its CE Mark as the product was not aligned with the Company’s core strategic focus. The impairment charge was recorded in selling, general & administrative expenses on the Company’s consolidated statements of operations.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration